Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-25-000062
Filing Date
2025-08-08
Accepted
2025-08-08 09:38:56
Documents
6
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 6-K q22025form6-k.htm 6-K 22028
2 EX-99.1 2025 SECOND QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsjune302025.htm EX-99.1 392876
3 EX-99.2 2025 SECOND QUARTER MD&A ex992-q22025mda.htm EX-99.2 259523
4 EX-99.3 Q2 2025 CERTIFICATION CEO ex993-q22025certificationx.htm EX-99.3 14046
5 EX-99.4 Q2 2025 CERTIFICATION CFO ex994-q22025certificationx.htm EX-99.4 13990
6 oncolyticslogotaglineblueaa.jpg GRAPHIC 355294
  Complete submission text file 0001129928-25-000062.txt   1142923
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 251196514
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)